Cell Therapeutics, Inc. (CTI) Projects Zevalin(R) Sales of $15 Million With Cash Flow Breakeven for Commercial Operatio...(s to have its initial complement of sale...)

Date:2/11/2008

s to have its initial complement of sales, marketing, and medical affairs infrastructure in place by the second quarter of 2008 under the leadership of Vice President of Commercial Operations, Jim Fong. With more than half of its targeted headcount already in place, CTI recently recruited Kenny Crouch as its National Sales Director. Crouch has more than 22 years of experience in sales, including 18 years in the healthcare industry and 11 years in biopharmaceutical management. Most recently, Crouch served as West Sales Director at CV Therapeutics where he commercialized and launched a novel cardiovascular therapy for ischemic heart disease. In addition, Gennyfer Santel, who joined CTI in December 2005, was recently promoted to Director of Marketing where she will be responsible for developing global strategic and tactical brand plans for CTI's products. Santel has more than 15 years of experience in medical communications and planning, most recently as Vice President, Integrated Services at ApotheCom Associates.

Operating Expense Reductions

In addition to Zevalin commercial activities, Bianco will outline CTI's plans to focus on preparing marketing applications for XYOTAX(TM) (paclitaxel poliglumex, CT-2103) and pixantrone (BBR 2778).

CTI expects to file a Marketing Authorization Application (MAA) for XYOTAX in Europe in March based on clinical trial data from the STELLAR trials. In addition to the MAA, CTI will prioritize its resources to the GOG212 trial, a clinical trial of XYOTAX in first-line maintenance ovarian cancer being performed by the Gynecologic Oncology Group (GOG). Interim results from this study are expected in the second half of 2009. The clinical trial of XYOTAX in combination with carboplatin in women with pre-menopausal estradiol levels who have first-line non-small cell lung cancer, known as the PGT307 trial, will be limited to U.S. sites only, until either approval of the MAA or until positive results from the GOG212 trial a
'/>"/>

SOURCE Cell Therapeutics, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related biology technology :

1. Cell Therapeutics, Inc. (CTI) to Present at 10th Annual BIO CEO & Investor Conference
2. Nile Therapeutics, Inc. to Present at Upcoming BIO CEO & Investor Conference
3. Velcura Therapeutics, Inc. Teams with International Discovery Sourcing Consultants to Develop New Therapeutic Molecules for Cancer and Bone Disease
4. Sonexa Therapeutics, Inc., Raises $30 Million in Series A Financing to Focus on Alzheimers Treatments
5. Cryo-Cell Announces Research Collaboration Agreement with Saneron CCEL Therapeutics, Inc.
6. Cell Therapeutics, Inc. (CTI) Shareholders Authorize Share Increase at Special Meeting of Shareholders
7. Velcura Therapeutics, Inc. Can Begin Clinical Trials Following Successful Investigational New Drug Application to U.S. FDA
8. Cell Therapeutics, Inc. (CTI) Prices $1.27 million (euros 856.000) Offering of Common Stock through Societe Generale
9. Cell Therapeutics, Inc. Announces Authorization to Publish Italian Listing Prospectus
10. Cell Therapeutics, Inc. (CTI) Hosts Conference Call to Discuss Update on Zevalin(R) Acquisition, CMS Reimbursement, and PIX301 Timeline
11. Pearl Therapeutics, Inc. Expands Its Senior Management Team With Top Talent in Clinical Development and Regulatory Affairs